Pathogenesis‐directed therapy of 2019 novel coronavirus disease

• Published in: Journal of medical virology Vol. 93; no. 3; pp. 1320 - 1342
• Main Authors: Stratton, Charles W., Tang, Yi‐Wei, Lu, Hongzhou
• Format: Journal Article
• Language: English
• Published: United States Wiley Subscription Services, Inc 01.03.2021
• Subjects: Abnormalities; Antibodies; Anticoagulants; Antiviral agents; Antiviral Agents - therapeutic use; Antiviral drugs; Autopsies; Autopsy; Calciferol; Cell-mediated immunity; Coagulation; Coronaviridae; coronavirus; Coronaviruses; COVID-19; COVID-19 - complications; COVID-19 - physiopathology; COVID-19 - therapy; Cytokines; Dexamethasone; Dietary supplements; Dimers; Disseminated intravascular coagulation; Documents; Fever; Fibrinogen; Gastroenteritis; Heparin; Humans; Humerus; Hypoxemia; Hypoxia; Hypoxia - prevention & control; Immunology; Infections; Inflammation; Inflammation - drug therapy; Influenza; Intravenous administration; Low molecular weights; Lung - pathology; Mechanical ventilation; Molecular weight; Nutrient deficiency; Oseltamivir; Oxygen; Oxygen saturation; Oxygen therapy; Pathogenesis; Pathophysiology; Patients; Pneumonia; Prophylaxis; Public health; Respiratory diseases; Reviewing; SARS-CoV-2 - pathogenicity; SARS‐CoV‐2 coronavirus; Severe acute respiratory syndrome; Severe acute respiratory syndrome coronavirus 2; Therapy; Thromboembolism; Thrombosis; treatment; Ventilation; Viral diseases; Viral Load - drug effects; Virology; Vitamin D; Vitamin deficiency; Zinc; pathogenesis; treatment; coronavirus; SARS-CoV-2 coronavirus; therapy

The 2019 novel coronavirus disease (COVID‐19) now is considered a global public health emergency. One of the unprecedented challenges is defining the optimal therapy for those patients with severe pneumonia and systemic manifestations of COVID‐19. The optimal therapy should be largely based on the p...